From financial results to new acquisitions, here are seven key updates from spine and orthopedic devicemakers since Feb. 5.

Zimmer Biomet shares at $105 reveal value at 13 times adjusted earnings, as the company continues to grow despite a GLP-1 ...

Medical device company Zimmer Biomet (NYSE:ZBH) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.3% year ...

Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from ...

Surgery Partners. In 2024, Surgery Partners added five new ASCs and two orthopedic ASCs in Chicago through a partnership with Duly Health. It also added over 230 physicians across orthopedics, spine ...

BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 ...

NeuroOne Medical Technologies Corporation ( NASDAQ: NMTC) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET ...

The global joint replacement devices market, valued at US$22.50 billion in 2023, is forecasted to grow at a robust CAGR of 4.8%, reaching US$23.42 ...

According to InvestingPro analysis, the company currently appears undervalued, with a "GREAT" overall financial health score of 3.08 out of 5. Despite the positive earnings, Zimmer Biomet's stock ...

Zimmer Biomet posted fourth-quarter revenue growth of 5% in constant currency, which is generally consistent with the preceding quarters in 2024. Why it matters: As Zimmer Biomet has pursued a ...

(Reuters) - Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on ...